Your browser doesn't support javascript.
loading
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard, Victor H; Obeng, Rebecca C; Cummings, Kara L; Petroni, Gina R; Ambakhutwala, Angela L; Chianese-Bullock, Kimberly A; Smith, Kelly T; Lulu, Amanda; Varhegyi, Nikole; Smolkin, Mark E; Myers, Paisley; Mahoney, Keira E; Shabanowitz, Jeffrey; Buettner, Nico; Hall, Emily H; Haden, Kathleen; Cobbold, Mark; Hunt, Donald F; Weiss, Geoffrey; Gaughan, Elizabeth; Slingluff, Craig L.
Afiliación
  • Engelhard VH; Beirne Carter Center for Immunology Research and Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA vhe@virginia.edu.
  • Obeng RC; Beirne Carter Center for Immunology Research and Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Cummings KL; Beirne Carter Center for Immunology Research and Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Petroni GR; Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Ambakhutwala AL; Beirne Carter Center for Immunology Research and Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Chianese-Bullock KA; Department of Surgery/Division of Surgical Oncology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Smith KT; Department of Surgery/Division of Surgical Oncology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Lulu A; Beirne Carter Center for Immunology Research and Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Varhegyi N; Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Smolkin ME; Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Myers P; Department of Chemistry, University of Virginia, Charlottesville, Virginia, USA.
  • Mahoney KE; Department of Chemistry, University of Virginia, Charlottesville, Virginia, USA.
  • Shabanowitz J; Department of Chemistry, University of Virginia, Charlottesville, Virginia, USA.
  • Buettner N; 7Medical Research Council Centre for Immune Regulation and Clinical Immunology Service, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.
  • Hall EH; Office of Clinical Research, University Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Haden K; Department of Surgery/Division of Surgical Oncology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Cobbold M; 7Medical Research Council Centre for Immune Regulation and Clinical Immunology Service, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.
  • Hunt DF; Department of Chemistry, University of Virginia, Charlottesville, Virginia, USA.
  • Weiss G; Medicine/Division of Hematology-Oncology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Gaughan E; Medicine/Division of Hematology-Oncology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Slingluff CL; Department of Surgery/Division of Surgical Oncology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
J Immunother Cancer ; 8(1)2020 05.
Article en En | MEDLINE | ID: mdl-32385144
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Vacunas contra el Cáncer / Inmunoterapia / Melanoma / Antígenos de Neoplasias Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Aged80 Idioma: En Revista: J Immunother Cancer Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Vacunas contra el Cáncer / Inmunoterapia / Melanoma / Antígenos de Neoplasias Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Aged80 Idioma: En Revista: J Immunother Cancer Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido